ESR1 and breast carcinoma: In breast cancer, TP53 mutations, typically missense or frameshift mutations that lead to a loss-of-function effect [68], are more frequent in estrogen receptor (ER)-negative breast cancer and are detected in up to 80% of all TNBC specimens [69].